ASH 2025 - AML im Umbruch?
From Hämatologie Shortcasts by Dr. med. Richard Schabath, Dr. med. Andreas Hausmann, Dr. med. Stephan Fuhrmann
December 17, 2025 · 33 min · Season 4 · Episode 17
About this episode
The episode discusses key developments in myeloid neoplasms, focusing on AML and MDS, with insights from ASH 2025.
People in this episode
Host: Dr. Andreas Hausmann
Guest: Prof. Dr. med. Thomas Schroeder
Topics covered
- myeloid neoplasms
- acute myeloid leukemia
- allogeneic stem cell transplantation
- FLT3 inhibition
- combination therapies
- clinical outcomes
Keywords
- AML
- MDS
- Gilteritinib
- Sorafenib
- HMA
- Venetoclax
- stem cell transplantation
- clinical trials
Mentioned in this episode
Organizations: Universitätsklinikum in Essen
Products: Gilteritinib, Sorafenib, HMA, Venetoclax
Books & works: VERONA-Studie
More episodes of Hämatologie Shortcasts
- Zwischen ASH und ASCO: Praxisrelevante Updates aus Lymphom, AML und Myelofibrose · June 11, 2026 · 18 min
- AML – Revolution oder Evolution? · February 27, 2026 · 26 min
- ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
- ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
- ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
- ASH 2025 – Neuigkeiten zur CLL · December 16, 2025 · 24 min
Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.